StockStory.org on MSN
NEO Q1 deep dive: High-value test expansion and commercial execution drive oncology growth
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results , with sales up 11.1% year on year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results